Pharmacodynamics of linezolid in a clinical isolate of Streptococcus pneumoniae genetically modified to express lux genes

被引:17
作者
Alloush, HM [1 ]
Salisbury, V
Lewis, RJ
MacGowan, AP
机构
[1] Univ W England, Fac Sci Appl, Bristol BS16 1QY, Avon, England
[2] Southmead Gen Hosp, Dept Med Microbiol, Bristol Ctr Antimicrobial Res & Evaluat, Bristol BS10 5NB, Avon, England
关键词
bioluminescence; Streptococcus pneumoniae; oxazolidinones;
D O I
10.1093/jac/dkg334
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
A bioluminescent clinical isolate of Streptococcus pneumoniae was used to test the real-time effects of the oxazolidinone antibiotic, linezolid, on metabolism compared with effects on cell replication. Viable counts and bioluminescence measurements showed that linezolid has little bactericidal effect, which was similar at minimum (6 mg/L), intermediate (13 mg/L) and maximum (20 mg/L) serum concentrations. The post-antibiotic effect, however, was shorter when measured by light output than by viable counts. The results demonstrate that bioluminescence provides a rapid and sensitive means of measuring the effect of antimicrobials on bacterial metabolism, and that the latter recovers earlier than commencement of cell replication after linezolid exposure.
引用
收藏
页码:511 / 513
页数:3
相关论文
共 11 条
[1]   In vivo pharmacodynamics of a new oxazolidinone (linezolid) [J].
Andes, D ;
van Ogtrop, ML ;
Peng, J ;
Craig, WA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (11) :3484-3489
[2]   Expression of lux genes in a clinical isolate of Streptococcus pneumoniae:: Using bioluminescence to monitor gemifloxacin activity [J].
Beard, SJ ;
Salisbury, V ;
Lewis, RJ ;
Sharpe, JA ;
MacGowan, AP .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (02) :538-542
[3]   Comparative activity of linezolid and other new agents against methicillin-resistant Staphylococcus aureus and teicoplanin-intermediate coagulase-negative staphylococci [J].
Betriu, C ;
Redondo, M ;
Boloix, A ;
Gómez, M ;
Culebras, E ;
Picazo, JJ .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 (06) :911-913
[4]   Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America:: 1997 results from the SENTRY antimicrobial surveillance program [J].
Doern, GV ;
Pfaller, MA ;
Kugler, K ;
Freeman, J ;
Jones, RN .
CLINICAL INFECTIOUS DISEASES, 1998, 27 (04) :764-770
[5]   Linezolid: An oxazolidinone antimicrobial agent [J].
Fung, HB ;
Kirschenbaum, HL ;
Ojofeitimi, BO .
CLINICAL THERAPEUTICS, 2001, 23 (03) :356-391
[6]   The post-exposure response of Enterobacteriaceae to ceftibuten [J].
MacKenzie, FM ;
Milne, KE ;
Gould, IM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 (01) :71-77
[7]   COMPARISON OF METHODOLOGIES USED IN ASSESSING THE POSTANTIBIOTIC EFFECT [J].
MACKENZIE, FM ;
GOULD, IM ;
CHAPMAN, DG ;
JASON, D .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1994, 34 (02) :223-230
[8]  
PHILIPS I, 1991, J ANTIMICROB CHEMOTH, V27, P1906
[9]   Use of a clinical Escherichia coli isolate expressing lux genes to study the antimicrobial pharmacodynamics of moxifloxacin [J].
Salisbury, V ;
Pfoestl, A ;
Wiesinger-Mayr, H ;
Lewis, R ;
Bowker, KE ;
MacGowan, AP .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 (06) :829-832
[10]   The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria [J].
Swaney, SM ;
Aoki, H ;
Ganoza, MC ;
Shinabarger, DL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (12) :3251-3255